Group items tagged

The immunobiology of mushrooms. Borchers AT, Krishnamurthy A, Keen CL, Meyers FJ, Gershwin ME. Exp Biol Med (Maywood). 2008 Mar;233(3):259-76. Review. PMID: 18296732 doi: 10.3181/0708-MR-227

Dietary supplementation with white button mushroom enhances natural killer cell activity in C57BL/6 mice. Wu D, Pae M, Ren Z, Guo Z, Smith D, Meydani SN. J Nutr. 2007 Jun;137(6):1472-7. PMID: 17513409

The effects of whole mushrooms during inflammation.\nYu S, Weaver V, Martin K, Cantorna MT.\nBMC Immunol. 2009 Feb 20;10:12.\nPMID: 19232107 \ndoi:10.1186/1471-2172-10-12\n

Hathcock JN, Shao A, Vieth R, Heaney R. \nRisk assessment for vitamin D.\nAm J Clin Nutr. 2007 Jan;85(1):6-18. Review.\nPMID: 17209171 [PubMed - indexed for MEDLINE]

Heaney RP. \nLong-latency deficiency disease: insights from calcium and vitamin D.\nAm J Clin Nutr. 2003 Nov;78(5):912-9. Review.\nPMID: 14594776 [PubMed - indexed for MEDLINE]

Vieth R, Chan PC, MacFarlane GD.Efficacy and safety of vitamin D3 intake exceeding the lowest observedadverse effect level.Am J Clin Nutr. 2001 Feb;73(2):288-94.PMID: 11157326 [PubMed - indexed for MEDLINE]

Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol.Am J Clin Nutr. 2003 Jan;77(1):204-10. Erratum in: Am J Clin Nut

de Lorgeril M, Salen P, Martin J-L, Monjaud I, Delaye J, Mamelle N:\nMediterranean diet, traditional risk factors and the rate of\ncardiovascular complications after myocardial infarction. Final report of the Lyon Diet Heart Study.\nCirculation 1999, Febr

Leaf A.\nDietary prevention of coronary heart disease: the Lyon Diet Heart Study.\nCirculation. 1999 Feb 16;99(6):733-5.

Valimaki VV, Alfthan H, Lehmuskallio E, Loyttyniemi E, Sahi T, Stenman UH, Suominen H, Valimaki MJ.\nVitamin D status as a determinant of peak bone mass in young Finnish men.\nJ Clin Endocrinol Metab. 2004 Jan;89(1):76-80.\nPMID: 14715830 [PubMed - indexe

Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006 Jul;84(1):18-28. Review. PMID: 16825677

Vieth R.Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety.Am J Clin Nutr. 1999 May;69(5):842-56. Review.PMID: 10232622 [PubMed - indexed for MEDLINE]

Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP, Holick MF, Hollis BW, Lamberg-Allardt C, McGrath JJ, Norman AW, Scragg R, Whiting SJ, Willett WC, Zittermann A. \nThe urgent need to recommend an intake of vitamin D that is

The beverage maté: a risk factor for cancer of the head and neck. Goldenberg D, Golz A, Joachims HZ. Head Neck. 2003 Jul;25(7):595-601. Review. PMID: 12808663 DOI: 10.1002/hed.10288

White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation. Grube BJ, Eng ET, Kao YC, Kwon A, Chen S. J Nutr. 2001 Dec;131(12):3288-93. PMID: 11739882

Anti-aromatase activity of phytochemicals in white button mushrooms (Agaricus bisporus). Chen S, Oh SR, Phung S, Hur G, Ye JJ, Kwok SL, Shrode GE, Belury M, Adams LS, Williams D. Cancer Res. 2006 Dec 15;66(24):12026-34. PMID: 17178902 doi: 10.1158/0008-5472.CAN-06-2206

Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Kidd P. Altern Med Rev. 2003 Aug;8(3):223-46. Review. PMID: 12946237 Th1 pathways typically produce activation of cytotoxic T lymphocytes (Tc), NK cells, macrophages, and monocytes, all of which can attack cancer cells and generally defend against tumors. 55 IFN-gamma and other Th1 cytokines are typically lower in advanced cancer patients, while the Th2 marker IL-4 can be higher or unchanged.56 Nodules of non-small cell lung cancer freshly removed from patients expressed a marked imbalance toward Th2, as did biopsy samples from basal cell carcinoma.57 In prostate cancer patients IL-2 was low (Th1) and IL-10 high.58 IL-10 is a confirmed Th1-suppressive cytokine, and heightened IL-10 is a common factor in cancer.55 IL-10 has a variety of suppressive effects that include inhibiting Th1 cytokine production, down-regulating APC and NK cell function, and lowering overall T-cell proliferation.57 Especially under the influence of IL-4 (Th2), tumor cells apparently up-regulate IL-10 that suppresses nearby killer cells. Tumor-derived IL-10 has been documented in lymphoma, ovarian carcinoma, melanoma, neuroblastoma, and renal cell and colon carcinoma.57 IL-12 is another cytokine that can be up-regulated by Th1 activity and inhibited by Th2.59 A low IL-12/IL-10 ratio was found in cervical cancer patients.55 Recent clinical studies suggest elevated IL-10 is predictive of a poor prognosis. 57 With both IL-4 and IL-10 being proven inhibitors of Th1 and promoters of Th2 activity, the recognized capability of cancerous tissue to suppress immunity is readily rationalized.